Business Standard

Lupin gains 3% as Vizag API facility receives EIR from USFDA

Brokerage firm Prabhudas Lilladher has upgraded Lupin's stock to 'Buy' from earlier 'Reduce' with target price of Rs 978

Lupin
Premium

Lupin

SI Reporter Mumbai
Shares of Lupin rose 3 per cent to Rs 863 on the BSE on Thursday after the company’s API (Active Pharmaceutical Ingredients) in Vizag received the establishment inspection report (EIR) from the US health regulator.

The pharmaceutical company today announced the receipt of the EIR from the United States Food and Drug Administration (USFDA) after closure of the inspection for its Vizag (Vishakhapatnam), India facility. The inspection for the API facility was conducted by the USFDA between January 13, 2020 and January 17, 2020, it said.

Lupin enjoys leadership position in the cardiovascular, anti-diabetic, and respiratory segments and

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in